Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular tolerance of tiotropium in healthy males
NCT02177305Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 1998
- Primary completion
- Dec 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in pupil diameter at 24 hours, Change in pupillary reflex at 24 hours and 2 more. Started Oct 1998; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02177305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177305.